Clinical Trials Logo

KRAS Activating Mutation clinical trials

View clinical trials related to KRAS Activating Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05669482 Recruiting - Metastatic Cancer Clinical Trials

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

RAMP205
Start date: March 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.

NCT ID: NCT05375994 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

RAMP204
Start date: August 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

NCT ID: NCT05074810 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

RAMP203
Start date: April 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.